Tag : BRENTUXIMAB VEDOTIN

The United States (US) Food and Drug Administration (FDA) has approved brentuximab vedotin (BV) in combination with lenalidomide and a rituximab product (Len + R) for adults with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more systemic therapies, including those with diffuse LBCL (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), who are ineligible for autologous stem cell transplantation (auto-HSCT) or CAR T-cell therapy.